Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data

G P Rubin *,1, C L Saunders 2, G A Abel 2, S McPhail 3, G Lyratzopoulos 2 and R D Neal 4

1 Evaluation, Research and Development Unit, School of Medicine, Pharmacy and Health, Wolfson Research Institute, University of Durham, Queen’s Campus, University Boulevard, Stockton-on-Tees TS17 6BH, UK; 2 Department of Public Health and Primary Care, Cambridge Centre for Health Services Research, University of Cambridge, Cambridge CB2 0SR, UK; 3 National Cancer Intelligence Network (NCIN), Public Health England, 5th Floor, Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK and 4 North Wales Centre for Primary Care Research, College of Health & Behavioural Sciences, Bangor University, Gwenfro Unit 5, Wrexham Technology Park, Wrexham LL13 7YP, UK

Background: For patients with symptoms of possible cancer who do not fulfil the criteria for urgent referral, initial investigation in primary care has been advocated in the United Kingdom and supported by additional resources. The consequence of this strategy for the timeliness of diagnosis is unknown.

Methods: We analysed data from the English National Audit of Cancer Diagnosis in Primary Care on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer relating to the ordering of investigations by the General Practitioner and their nature. Presenting symptoms were categorised according to National Institute for Health and Care Excellence (NICE) guidance on referral for suspected cancer. We used linear regression to estimate the mean difference in primary-care interval by cancer, after adjustment for age, gender, and the symptomatic presentation category.

Results: Primary-care investigations were undertaken in 3198/5036 (64%) of cases. The median primary-care interval was 16 days (IQR 5–45) for patients undergoing investigation and 0 days (IQR 0–10) for those not investigated. Among patients whose symptoms mandated urgent referral to secondary care according to NICE guidelines, between 37% (oesophagus) and 75% (pancreas) were first investigated in primary care. In multivariable linear regression analyses stratified by cancer site, adjustment for age, sex, and NICE referral category explained little of the observed prolongation associated with investigation.

Interpretation: For six specified cancers, investigation in primary care was associated with later referral for specialist assessment. This effect was independent of the nature of symptoms. Some patients for whom urgent referral is mandated by NICE guidance are nevertheless investigated before referral. Reducing the intervals between test order, test performance, and reporting can help reduce the prolongation of primary-care intervals associated with investigation use. Alternative models of assessment should be considered.

There are an estimated 300 million consultations in general practice in England annually (90% of all patient contacts with health care) (Hippisley-Cox and Vinogradova, 2009). A major challenge for primary-care clinicians is to discriminate, often on the basis of undifferentiated or non-specific symptoms, between patients with self-limiting illness and those with significant disease.
Cancer symptoms typically have low positive predictive values and present a particular challenge in this respect (Hamilton, 2009). Nevertheless, prompt identification and referral for investigation of patients with suspected cancer is a major public and policy concern (Department of Health, 2007; Macmillan Cancer Support, 2014), based on a widely held view that delays have a detrimental effect on outcome. The evidence is not as yet definitive. Although some studies have shown an association between longer time to diagnosis and poorer clinical outcomes (Richards et al., 1999; Torring et al., 2013), confounding by patients with advanced disease at presentation can make their interpretation problematic (Neal, 2009). Meanwhile, prolonged time to diagnosis results in psychological distress and sub-optimal patient experience (Risberg et al., 1996; Rarer Cancer Foundation, 2011). Clinical guidance for general practitioners (GPs) on high-risk features warranting urgent referral for suspected cancer has been produced in a number of countries, and in England by NICE in 2005 (National Institute for Health and Care Excellence (2005)). Many cancer patients, however, present to their GP with lower-risk features (Hamilton, 2010). A more recent approach to improving cancer outcomes in England has been to increase access for GPs to diagnostic tests supported by guidance on their use (Department of Health, 2012a).

In the 3 months before diagnosis, Danish patients with cancer have around 10 times as many diagnostic investigations as the reference population, some instigated by GPs (Christensen et al., 2012). Most studies of GPs’ use of investigations has addressed issues of test use (Jellema et al., 2010) and efficiency (Verstappen et al., 2003; Schoen et al., 2004). It is uncertain, however, whether initial investigation of cancer symptoms in primary care delays referral for specialist assessment. This question is central to clinical practice and cancer diagnosis.

In order to answer the question of whether, in patients with symptoms suggestive of cancer, primary-care investigations are associated with less prompt referral, we analysed data from the English National Audit of Cancer Diagnosis in Primary Care, conducted during 2009/10 and containing information on 18,879 patients diagnosed with cancer in that period (Rubin et al., 2011).

PATIENTS AND METHODS

The methods used in collection of the source data are described in detail elsewhere (Rubin et al., 2011). In brief, anonymous data were collected by GPs or other primary-care professionals in an estimated total of 1170 general practices (~14% of all practices in England) that participated voluntarily in an audit of cancer diagnosis in primary care. All patients of those practices, who were diagnosed with cancer, typically during a defined period of up to 12 months, were included in the audit. Patients with screen-detected cancer, in situ cancer, and non-melanoma skin cancer were excluded. The age, gender, and cancer diagnosis case-mix of the audited population is representative of the population-based cancer incidence statistics, and participating practices are similar to non-participating practices in their (former) cancer networks (Lytratzopoulos et al., 2013a). We analysed data on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer. These six cancer sites were selected because of small numbers. We defined primary-care interval as the period in days from first presentation to a GP with a relevant symptom to the date of first specialist referral for further assessment. The audit also collected the date of the first appointment with a specialist, but did not collect the date of diagnosis.

Gender and age were recorded from the patient medical records, the latter categorised for this study into six groups 15–44, 45–54, 55–64, 65–74, 75–84 and 85 +.

Data were extracted from the audit data set in relation to two questions ‘Did the GP order any investigations’ and ‘If yes, please list the investigations in order’. Practice staff were asked to identify any investigations undertaken prior to referral. Responses to the first question were coded as yes, no, or missing, and responses to the second question were used to create five binary variables coding whether or not the patient had had any of five common investigations: blood test; chest X-ray; ultrasound scan; CT or MRI scan; endoscopic investigation.

Clinical presentation. Free text audit records in response to the question ‘What was the main presenting symptom?’ were categorised in two stages. First, and separately by cancer, the presenting symptom(s) was classified into between 20 and 37 groups (Appendix Table A1). These were agreed by three clinicians (GPR, RDN, GL) and then independently assigned by them. Disagreements were resolved by discussion between coders. Where more than one symptom was described, the main symptom was taken as the first stated, unless a NICE Clinical Guideline (CG)27-mandated (‘alarm’) symptom appeared later in the list.

Second, patients were classified on the basis of their presenting symptom(s) and age into five groups according to CG27; mandatory referral; possibly mandatory referral (insufficient information provided on qualifying conditions (e.g., severity, duration, frequency) to be definitive); mandatory investigation; possibly mandatory investigation (as above); no mandatory action. Some presenting symptoms (e.g., ascites, haematemesis) were not specifically mentioned in CG27 as requiring urgent referral, but the clinical consensus was that this would be best practice. These were included in the ‘mandatory referral’ group. Coding was age specific for those symptoms for which CG27 recommendations were age-conditional. For multivariable analysis, ‘possible referrals’ were grouped with ‘no action’ for ovarian and oesophageal cancers because of small numbers.

Statistical analysis. We describe the primary-care interval distribution using the mean, median, 25th, 75th, and 90th centiles. Stratified by cancer diagnosis, we calculated the percentages of patients investigated by their GP in each of the five NICE CG27 referral recommendation groups.

We calculated the mean difference in primary-care interval among those patients investigated in primary care and those who were not. To determine whether the association between primary-care investigations and primary-care interval can be attributed to different clinical presentations (i.e., whether patients who are most likely to be investigated are simply those who present with non-specific symptoms and have a longer primary-care interval for this reason), we used linear regression to estimate the mean difference in primary-care interval by investigation status, adjusting for age, gender, and the NICE referral category, separately by cancer. 95% Confidence intervals were estimated using bias corrected and accelerated bootstrap estimation, and where they exclude zero, the differences between the two groups were taken to be significant at $P < 0.05$. Analyses were repeated for 99.99% confidence intervals.

We performed a number of sensitivity analyses investigating the impact of how the primary-care interval, primary-care investigation use and clinical presentation were parameterised (see Appendix Tables for details). Further, we performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the
number of days between referral from primary care and first patient contact in secondary care). We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use.

RESULTS

The derivation of the analysis sample is shown in Figure 1. In descriptive analyses, primary-care investigations were undertaken in 3198/5036 of included cases (64%), ranging from 43% for oesophageal cancer to 80% for lung cancer. The median primary-care interval across all six cancer sites was 16 (IQR 5–45) days for those who had one or more investigation, and 0 (IQR 0–10) days for those who had no investigation. The corresponding mean intervals were 41 days and 17 days, and did not differ by age or gender. The difference in the median interval by investigation status was considerably greater at the 75th (10 days non-investigated, 44 days investigated patients) and 90th centiles (45 days and 106 days, respectively) (Table 1).

In unadjusted analyses, individual investigations lengthened the mean primary-care interval by between 5 days (chest X-ray) and 32 days (endoscopy), whereas undertaking more than one test in primary care added a mean of 8 days (Table 2). For individual cancer sites, any investigation significantly extended the mean primary-care interval by between 20 days (ovarian) and 30 days (stomach) (Table 2). When individual cancers were considered by NICE referral category, investigation was more likely if NICE CG27 mandated this or if no action was mandated. The proportion of patients presenting with symptoms for which NICE CG27 mandated urgent referral was 10%, 9%, 5%, 64%, 24%, and 37% for colorectal, ovarian, lung, oesophageal, pancreatic, and stomach cancer, respectively. Nevertheless, a substantial proportion of patients whose symptoms mandated urgent referral were investigated in primary care, ranging from 37% (oesophagus) to 75% (pancreas) (Table 3).

In linear regression analyses, stratified by cancer, that adjusted for age, sex, and the NICE referral category, adjustment for these factors explained very little of the mean observed additional days associated with investigation, but the effect for pancreatic cancer ceased to be significant (Table 4). Alternative parameterisations of the primary-care interval, investigation use, or clinical presentation categories made minimal difference to these findings (Appendix Tables A3–A5).

Among those patients for whom data on number of consultations prior to referral were available, 965/2095 (46.1%) of those consulting once were investigated, while 1058/1240 (85.3%) of those consulting 3+ times were investigated.

Finally, in order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals, we examined the association between investigations in primary care and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic). For all cancers, except pancreatic cancer, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated. We find no evidence that longer primary-care intervals are offset by shorter referral intervals in patients who are investigated in primary care (Appendix Table A6). Because date of diagnosis did not form part of the data items collected for the audit, we were unable to examine the effect of investigations on total diagnostic interval.

DISCUSSION

We found that for six specified cancers, investigation in primary care of the presenting symptom(s) was associated with later referral for specialist assessment. This difference in the mean primary-care interval ranged from an additional 20 to 30 days depending on the cancer site, and was independent of whether the patient presented with alarm symptoms. For four of the six cancers studied, the difference increased with the number of tests undertaken.

The principle that patients with symptoms are initially assessed in primary care in order that only a proportion are then more extensively assessed by specialists (the gatekeeping function) is a key feature of health-care systems in which primary care features strongly. It contributes to their better health outcomes and efficiencies (Starfield et al., 2005), although an ecological association with poorer

---

Diagram Description:

Figure 1. Flow diagram: derivation of the analysis sample.

6307 Patients in the NACDPC database with 6 cancers; colorectal, ovarian, lung, oesophageal, pancreatic, stomach

- 6173 Patients with a valid age > 15 years
- 5073 Patients with a valid outcome measure (primary care interval)
- 5036 Patients included in the final analysis sample

134 Patients with age < 15 (n=1) or missing age (n=133)

1100 Patients with missing primary care interval

37 Patients with missing information on GP requested investigations
cancer 1-year survival has also been described (Vedsted and Olesen, 2011). Investigation in primary care is most strongly associated with perceived medical need, although a minority of investigations are a consequence of patient preference (Little et al, 2004). Where the alternative is specialist referral, investigation in primary care may result in the primary-care interval being prolonged, since additional consultations are needed to communicate results, and multiple consultations are associated with longer primary-care intervals (Lyrratzopoulos et al, 2013b). We found that 85% of patients consulting three or more times had undergone investigation, compared with 46% of those consulting once. The literature is sparse on the effect of investigations in primary care on time to diagnosis, although a study of patients with colorectal cancer found that those who were not investigated by the faecal occult blood test had a significantly shorter median diagnostic interval than those who were (Hogberg et al, 2013). Further, a qualitative study of patients with testicular cancer identified waiting time for GP-initiated investigations as a factor in late diagnosis (Chapple et al, 2008). However, failure to investigate may be also associated with referral being deferred. In a study of GP-reported quality deviations in 5711 patients with cancer, failure to order relevant investigations was associated with a prolonged diagnostic interval (Jensen et al, 2014), whereas diagnostic delay for tuberculosis has been associated with failure of the first doctor consulted to order a sputum test or chest X-ray (Calder et al, 2000).

Strengths and limitations. This is the first study to explicitly determine the effect of GP-initiated investigations on speed of referral for specialist assessment. Its strengths include the relatively large number of cases for each cancer site, the completeness of data on presenting symptom(s) and consultations, and the direct extraction of information from the primary-care record. The study team included experienced clinicians, ensuring that the complex task of coding clinical data was accurately completed. There are several limitations that we acknowledge. Because participation of general practices in the audit was voluntary and potentially biased towards those most interested in cancer care, the findings may represent ‘better’ practice. However, the audit patient population was similar to the incident cancer cases in England (Rubin et al, 2011) while the characteristics of participating practices were similar to non-participating practices of the same (former) cancer network (Lyrratzopoulos et al, 2013b). Nevertheless, these practices may have been more interested in cancer diagnosis and management and more likely to investigate patients with suspicious symptoms. Practices were typically required to audit a continuous sample of cases occurring in a specified period, and there was no evidence of significant exclusion of cases (Rubin et al, 2011).

Data were extracted from clinical records and hospital correspondence. There was no validation of the data, but in all cases data were reviewed at a practice meeting and checked for completeness and face validity by a cancer network clinical lead. There is scope for errors of interpretation during data extraction, for example, in deciding on the date of first consultation. The potential sources of error in studies of diagnostic intervals have been well described (Weller et al, 2012), but the methodology used by the audit conform to best practice in the field Weller et al, 2012). Finally, 1100 (17.9%) cases were excluded because both of the dates required to estimate the primary-care interval were not available. Many of these were patients whose pathway to diagnosis

| Table 1. Patient characteristics, mean and median (percentile) primary-care interval |
|---------------------------------|-------|------|--------------|-------------|------------|-----------|
|                                 | N     | Mean | Median       | 25th Percentile | 75th Percentile | 90th Percentile |
| All                             | 5036  | 32.5 | 8            | 0            | 34         | 87        |
| Sex                             |       |      |              |              |            |           |
| Female                          | 2413  | 33.1 | 9            | 0            | 36         | 88        |
| Male                            | 2623  | 31.9 | 8            | 0            | 32         | 85        |
| Age                             |       |      |              |              |            |           |
| 15–44                           | 150   | 36.9 | 7.5          | 0            | 43         | 113       |
| 45–54                           | 405   | 30.3 | 8            | 0            | 34         | 75        |
| 55–64                           | 1030  | 31.1 | 8            | 0            | 33         | 85        |
| 65–74                           | 1503  | 32.0 | 8            | 0            | 34         | 83        |
| 75–84                           | 1430  | 33.6 | 9            | 0            | 36         | 88        |
| 85+                             | 518   | 34.2 | 7            | 0            | 32         | 100       |
| Cancer diagnosis                |       |      |              |              |            |           |
| Colorectal                      | 2111  | 33.0 | 6            | 0            | 30         | 94        |
| Ovarian                         | 345   | 21.5 | 7            | 0            | 25         | 54        |
| Lung                            | 1494  | 34.5 | 13           | 3            | 39         | 83        |
| Oesophageal                     | 513   | 26.3 | 6            | 0            | 31         | 75        |
| Pancreatic                      | 327   | 33.0 | 7            | 0            | 32         | 96        |
| Stomach                         | 246   | 43.2 | 13           | 0            | 58         | 132       |
| Investigations in primary care  |       |      |              |              |            |           |
| No                              | 1838  | 17.4 | 0            | 0            | 10         | 44        |
| Yes                             | 3198  | 41.2 | 16           | 5            | 45         | 106       |
### Table 2. Primary-care investigations and primary-care interval, by cancer

|                | All               | Colorectal        | Ovarian          | Lung             | Oesophageal      | Pancreatic       | Stomach          |
|----------------|-------------------|-------------------|------------------|------------------|------------------|------------------|------------------|
|                | N                 | Mean   | Median | N       | Mean   | Median | N     | Mean   | Median | N     | Mean   | Median | N     | Mean   | Median |
| Any investigation in primary care | No*              | 1838  | 17.4   | 0       | 967   | 18.6   | 0     | 105   | 7.5    | 0     | 294   | 17.1   | 1     | 293   | 15.5   | 0     | 98    | 24.9   | 0     |
|                | Yes               | 3198  | 41.2   | 16      | 1144  | 45.3   | 17    | 240   | 27.7   | 13    | 1200  | 38.9   | 16    | 220   | 40.7   | 21    | 246   | 38.8   | 13    |
| Blood test     | No                | 2996  | 26.3   | 4       | 1140  | 23.4   | 1     | 195   | 19.5   | 2     | 1058  | 32.6   | 11    | 350   | 19.4   | 1     | 122   | 23     | 0     |
|                | Yes               | 2040  | 41.6   | 15      | 971   | 44.4   | 16    | 150   | 24.1   | 13    | 436   | 39.5   | 17    | 163   | 41.2   | 21    | 205   | 39     | 12    |
| Chest X-ray    | No                | 3908  | 31.4   | 6       | 2070  | 33.3   | 6     | 327   | 21.1   | 7     | 464   | 31.9   | 7     | 494   | 25.9   | 4     | 314   | 31.5   | 7     |
|                | Yes               | 1128  | 36.2   | 16      | 41    | 36.6   | 12    | 18    | 29.2   | 15.5  | 1030  | 35.8   | 15    | 19    | 37    | 27    | 13    | 68.9   | 39    | 7     |
| Ultrasound     | No                | 4546  | 30.9   | 7       | 1979  | 31.8   | 5     | 186   | 14.4   | 2     | 1455  | 34.3   | 13    | 497   | 25.3   | 5     | 211   | 20.8   | 3     |
|                | Yes               | 490   | 47.7   | 20      | 132   | 50.8   | 21.5  | 159   | 29.9   | 14    | 39    | 44.3   | 22    | 16    | 56.8   | 33    | 116   | 55.3   | 21    |
| CT/MRI         | No                | 4928  | 31.9   | 8       | 2094  | 32.5   | 6     | 338   | 20.9   | 7     | 1420  | 33.6   | 12    | 511   | 26.3   | 6     | 320   | 33.2   | 7     |
|                | Yes               | 108   | 56.9   | 35      | 17    | 95.1   | 39    | 7     | 54.1   | 34    | 74    | 52.9   | 35    | 2     | 20.5   | 20.5  | 7     | 26     | 13    |
| Endoscopy      | No                | 4861  | 31.4   | 8       | 2022  | 31.1   | 5     | 341   | 21.7   | 7     | 1484  | 34.4   | 13    | 478   | 25.1   | 5     | 314   | 30.8   | 7     |
|                | Yes               | 175   | 63.1   | 20      | 89    | 76.7   | 20    | 4     | 7.5    | 7.5   | 10    | 56.4   | 40.5  | 35    | 43.2   | 15    | 13    | 86.7   | 49    | 24    |
| Count of any of the above five investigations | 0*               | 1952  | 19.5   | 0       | 1031  | 20.0   | 0     | 108   | 8.3    | 0     | 312   | 22.4   | 2     | 315   | 17.7   | 0     | 82    | 15.9   | 0     |
|                | 1                 | 2301  | 38.7   | 14      | 923   | 42.4   | 14    | 147   | 30.1   | 11    | 809   | 37.7   | 14    | 162   | 37.3   | 15    | 148   | 22.9   | 7.5   |
|                | 2                 | 783   | 46.9   | 21      | 157   | 63.9   | 23    | 90    | 23.3   | 14    | 373   | 38.1   | 20    | 36    | 52.1   | 32.5  | 97    | 63     | 22    | 30    | 79.8   | 21    |

Abbreviations: CT = computed tomography; MRI = magnetic resonance tomography.

*The numbers in these two groups are slightly different as the first two rows include patients who have had any investigation in primary care, but the bottom three rows are counts based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).
interval resulting from investigations for five out of six cancers. First, we have observed a net lengthening of referral investigations compared with those without. These conditions are and the within-hospital interval to diagnosis would need to be total diagnostic interval, either or both of the referral interval secondary-care delays, and therefore no overall lengthening of that patients investigated in primary-care experience shorter shorter referral interval. Moreover, for the hypothesis to be true adding to the length of the primary-care interval, did not result in a interval. However, we observed that use of investigations, although adding to the length of the primary-care interval, did not result in a shorter referral interval. Moreover, for the hypothesis to be true that patients investigated in primary-care experience shorter secondary-care delays, and therefore no overall lengthening of the total diagnostic interval, either or both of the referral interval and the within-hospital interval to diagnosis would need to be substantially shorter for those patients with primary-care investigations compared with those without. These conditions are unlikely. First, we have observed a net lengthening of referral interval resulting from investigations for five out of six cancers. bypassed primary care, for example, through direct presentation to an emergency department. Others may have been seen by the GP, but the omission of dates of the first encounter and/or referral was not identified during the checking process prior to submission of data to the audit. All investigations included were part of the primary-care appraisal process, but no judgement was made on their appropriateness or their context within the episode of care. It is possible that some were unhelpful or irrelevant to the diagnostic process and unnecessarily prolonged the primary-care interval. Details of the precise nature of blood or urine tests or the sites examined by CT, MRI, or endoscopy were not a specific requirement of the precise nature of blood or urine tests or the sites examined by CT, MRI, or endoscopy were not a specific requirement of practices participating in the audit. Because the audit data were provided in an anonymous form, we were unable to link them to cancer registration and hospital record-derived data. This would have allowed us to determine, for those patients not investigated in primary care, whether investigation(s) were then undertaken in secondary or tertiary care and the effect of investigations in different settings on the total diagnostic interval. However, we observed that use of investigations, although adding to the length of the primary-care interval, did not result in a shorter referral interval. Moreover, for the hypothesis to be true that patients investigated in primary-care experience shorter secondary-care delays, and therefore no overall lengthening of the total diagnostic interval, either or both of the referral interval and the within-hospital interval to diagnosis would need to be substantially shorter for those patients with primary-care investigations compared with those without. These conditions are unlikely. First, we have observed a net lengthening of referral interval resulting from investigations for five out of six cancers.

Second, as use of investigations is associated with extending of the primary-care interval by a median of +16 days and a mean of +24 days, within-hospital diagnostic processes would need to be extraordinarily fast to compensate for these prolonged intervals. It should also be noted that in 2011/12 87.3% of patients commenced treatment within 62 days of referral, and 98.4% commenced treatment within 31 days of a diagnosis being made (Department of Health, 2012b). Moreover, the most frequent primary-care investigations were blood tests and chest X-rays, tests that do not typically provide the definitive diagnostic information necessary to establish the diagnosis of cancer, and would be unlikely to result in any substantial shortening of diagnostic intervals within secondary or tertiary care.

We selected the NICE referral category as our primary method for categorising patients’ presenting symptoms. We adjusted for symptom status using a range of complementary analytical approaches, all of which indicated that the degree of confounding by symptom status (in respect of the association between investigation and prolonged primary-care interval) is trivial. In other words, whether patients present with non-specific symptoms or obvious alarm symptoms, investigations are always associated with a longer primary-care interval.

Implications for practice. Our findings are generalisable to health systems in which GPs act as gatekeepers to specialist care, but may be modified by differences in access to diagnostic tests. A substantial proportion of patients underwent investigation when their symptoms fulfilled NICE CG27 criteria for urgent referral. There are several possible explanations for this. Disparaging views from specialists about ‘abuse’ by GPs of the urgent referral pathway.
may make some prefer to have additional evidence in the form of a confirmatory test result before making a referral (Mathew and Desai, 2009). The NICE criteria typically represent a risk of cancer in the region of 5–10%, the large majority not having the disease, and some GPs may use investigations as means of increasing the probability of cancer prior to making a decision about referral. It is also possible that some patients present in a context that causes the GP to modify their preferred course of action. For example, the patient may have been investigated in the past for the same problem, have severe co-morbidities, or may be reluctant to be referred to a specialist. Some GPs may consider it desirable, or have been advised that it is, for the results of baseline investigations to be available at the first specialist attendance (Barking, Havering and Redbridge University Hospital, 2014). Significant event analyses and case-note review studies are required to further establish the circumstances surrounding such ‘guideline violations’ (Mitchell et al, 2013; Singh et al, 2013).

Finally, certain investigations available to GPs are the definitive diagnostic tests, e.g., gastroscopy for suspected oesophagogastric cancer, and may be as readily available in primary as in specialist care. Other diagnostic tests, however, take longer to complete when ordered from primary care and may not be sufficiently comprehensive. In England, the median time from request to test for non-obstetric ultrasound investigation is longer for GP requests (19–27 days) than for all request sources combined (12–16 days) (NHS England, 2013). If investigations are undertaken in patients for whom urgent referral is indicated, the request should be concurrent with referral.

Because tests ordered in primary care may not be done or reported as promptly as those ordered from secondary care, our findings point to a need for investigative services to be provided to a comparable standard regardless of source of request. This should be accompanied by improved systems in primary care that ensure that a patient is rapidly reviewed once results are received. They also provide some support for models of service delivery in England that permit the rapid specialist assessment of patients with lower-risk symptoms, either by a lowering of the thresholds for urgent (2 weeks) referral for suspected cancer or the provision of diagnostic centres.

Time may be used as a diagnostic tool in primary care (Heneghan et al, 2009). Symptoms are seen by GPs at an earlier stage of development than in secondary care, and time allows the clinician to observe whether relatively undifferentiated symptoms develop more specific characteristics or resolve spontaneously. Investigations may form a part of this temporising approach while also being part of a safety-netting strategy (Almond et al, 2009).

These findings are the first step in determining the most effective diagnostic strategies for managing patients with symptomatic presentation of cancer. It will be important to understand the impact of primary-care investigation on secondary-care intervals, since these may plausibly be shortened, and on total diagnostic delay. Until then, no firm recommendations can be made on the merits or demerits of primary-care investigation. There is a need to understand the comparative clinical and health economic efficiency of strategies that encourage early primary-care investigation, compared with those that encourage either expectant management with limited testing and urgent referral if symptoms persist or worsen, or early referral without prior investigation.

**Table 4. Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age, sex and NICE guideline referral category**

| Mean additional primary-care interval (in days) among patients where investigations were performed | Number of cases | Unadjusted | Adjusted for age, sex, and clinical presentation | P-valuea |
|---|---|---|---|---|
| Colorectal | | | | |
| Not investigated | 967 | Reference | 26.7 (20.8–33.0) | Reference 25.7 (19.5–31.7) | P<0.0001 |
| Investigated | 1144 | | | |
| Ovarianb | | | | |
| Not investigated | 105 | Reference | 20.1 (13.6–27.5) | Reference 18.4 (12.2–25.5) | P<0.0001 |
| Investigated | 240 | | | |
| Lung | | | | |
| Not investigated | 294 | Reference | 21.8 (15.3–27.6) | Reference 23.6 (16.8–30.0) | P<0.0001 |
| Investigated | 1200 | | | |
| Oesophagealb | | | | |
| Not investigated | 293 | Reference | 25.3 (16.7–34.8) | Reference 22.3 (13.2–32.4) | P<0.0001 |
| Investigated | 220 | | | |
| Pancreaticb | | | | |
| Not investigated | 81 | Reference | 23.2 (5.0–38.1) | Reference 17.1 (~ 1.9–30.6) | P>0.05 |
| Investigated | 246 | | | |
| Stomach | | | | |
| Not investigated | 98 | Reference | 30.4 (15.1–48.2) | Reference 29.3 (14.0–45.8) | P<0.0001 |
| Investigated | 148 | | | |

Abbreviation: NICE = National Institute for Health and Care Excellence

a5% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The P-value (P>0.05) presented for pancreatic cancer reflects that this 95% confidence interval crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99% confidence intervals were re-estimated for the same model and these also did not cross zero, P<0.0001 is correspondingly presented.

bPossible referrals’ grouped with ‘No action’ in multivariable analysis because of small numbers.

cAge 15–44 years grouped with age 55–64 years because of small numbers.

**ACKNOWLEDGEMENTS**

RDN receives funding from Public Health Wales and Betsi Cadwaladr University Health Board. GL is supported by a Post-Doctoral Fellowship by the National Institute for Health Research (PDF-2011-04-047). We are grateful to all primary-care professionals in participating practices for collecting, collating and submitting anonymous data to the National Audit of Cancer Diagnosis in Primary Care; Cancer Networks, the Royal College of General Practitioners and the National Cancer Action Team for supporting the audit, and the National Clinical Intelligence Network (NCIN) for providing the data. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the RCGP, the National Institute for Health Research or the Department of Health.
GPR, GL, RDN, GAA and CS designed the study. GL, GAA and CLS analysed the data and all authors interpreted it. GPR wrote the first draft with additions and revisions by all authors.

REFERENCES

Almond S, Mant D, Thompson M (2009) Diagnostic safety-netting. Br J Gen Pract 59: 872–874.

Barking, Havering and Redbridge University Hospital (2014) Guidelines for referral of suspected upper GI cancer http://www.bhrhospitals.nhs.uk/Downloads/services/bhrut-cancer-form-uppergi-0409.pdf.

Bowles EA, Tizzuto L, Wiese CJ, Kirlin B, Greene SM, Clauser SB, Wagner EH (2008) Understanding high quality cancer care. Cancer 112: 934–942.

Calder L, Gao W, Simmons G (2000) Tuberculosis: reasons for diagnostic delay in England. NZ Med J 113: 83–85.

Chapple A, Ziebland S, McPherson A (2004) Qualitative study of men’s perceptions of why treatment delays occur in the UK for testicular cancer. Br J Gen Pract 54: 25–32.

Cheyne L, Foster C, Lovatt V, Hewitt F, Cresswell L, Fullard B, Fear J, Darby M, Robertson R, Plant PK, Milton R, Callister MEJ (2012) Improved lung cancer survival and reduced emergency diagnoses resulting from an early diagnosis campaign in Leeds 2011. Thorax 67(Suppl 2): A44.

Christensen KG, Fenger-Gron M, Flarup KR, Vedsted P (2012) Use of general practice, diagnostic investigations and hospital services before and after cancer diagnosis—a population-based nationwide registry study of 127000 incident adult cancer patients. BMC Health Serv Res 12: 224.

Danish National Board of Health (2010) Krenflplan III. Styrket indsat på kraftområdet – et sundhedsfagligt opløg. The Danish National Board of Health: Copenhagen, Denmark.

Department of Health (2007) Cancer Reform Strategy. Department of Health: London, UK.

Department of Health (2012a) Direct Access to Diagnostic Tests for Cancer: Best Practice Referral Pathways for General Practitioners (Gateway Ref 16913). Department of Health: London, UK.

Department of Health (2012b) Waiting Times for Cancer Services 2011-2012. Department of Health: London, UK.

Hamilton W (2009) The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer 101: S80–S86.

Hamilton W (2010) Cancer diagnosis in primary care. Br J Gen Pract 60: 121–128.

Henehan C, Glazioso P, Thompson M, Rose P, Balla J, Lasserson D, Scott C, Perera R (2009) Diagnostic strategies used in primary care. BMJ 338: b946.

Hippisley-Cox J, Vinogradova Y (2009) Trends in Consultation Rates in Primary Care and Health System Performance: Adults’ Experiences in Five Countries. Health Affairs W4: 487–503.

Singh H, Giardina TD, Meyer AN, Forjuoh SN, Menzies D. Understanding of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer 106: 2187–2198.

Verstappen WH, van der Wijden T, Sijbrandij J, Smeets I, Hermens J, Grimshaw J, Grol RP (2003) Effect of a practice-based strategy on test ordering performance of primary care physicians: a randomised trial. JAMA 289: 2407–14.

Weller D, Vedsted P, Rubin G, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, Hoon S, Suth M, Beyer M, Neal RD (2012) The Aarhus Statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer 106: 262–1267.
### Table A1. Symptom groups by cancer

| Oesophageal and gastric cancer | Lung cancer | Ovarian cancer | Colorectal cancer | Pancreatic cancer |
|-------------------------------|-------------|----------------|-------------------|------------------|
| Dysphagia                     | Haemoptysis | Ultrasound suggestive of ovarian cancer | Rectal bleeding | Obstructive jaundice |
| Early satiety                 | Chest/shoulder pain | Post-menopausal bleeding | Altered bowel habit (to looser stool) | Thromboembolic disease |
| Nausea, vomiting              | Dyspnoea    | Persistent intermenstrual bleeding (with a negative pelvic examination) | Abdominal mass | Bleeding per rectum/melaena |
| Dyspnea                       | Weight loss | Abdominal or pelvic mass not of gastrointestinal or urological origin | Rectal mass | Diabetic ketoacidosis/new onset diabetes/loss of known diabetes control |
| Reflux                        | Chest signs | Abdominal or pelvic pain or discomfort | Anaemia | Altered bowel habit |
| Pain (epigastric, abdominal, chest) | Hoarseness | Abdominal bloating/distension/swelling/fullness | Weight loss | Nausea and vomiting |
| Anorexia                      | Clubbing    | Urinary symptoms (including incontinence and retention) | Abdominal pain or tenderness | Gastro-oesophageal reflux disease |
| Fatigue, malaise              | Chest X-ray/supraclavicular lymph nodes | Unexplained weight loss | Bloating/distension | General malaise |
| Weight loss                   | Cough       | Fatigue/tiredness/malaise/unwell/exhaustion | Malaise | Bloating |
| Bowel disturbance             | Features suggesting metastases | Change in bowel habit to diarrhoea or alternating diarrhoea/constipation | Asymptomatic or incidental, including surveillance | Biliary colic |
| Iron deficiency anaemia       | Abnormal chest X-ray | Acute surgical/medical emergency | Cough/shortness of breath |
| Haematemesis/melaena          | Superior vena cava obstruction | Vaginal discharge or other abnormal vaginal bleeding | Constipation | Weight loss |
| Dizziness                     | Stridor     | Anaemia | Nausea/vomiting | Urinary tract infection/other urinary symptoms |
| Upper abdominal mass          | Loss of appetite | Chest symptoms | Other pain | anaemia |
| Asymptomatic or incidental finding | Thrombocytosis | Pulmonary embolus or deep vein thrombosis | Defaecation problems | Back pain |
| Pain (other)                  | Abnormal spirometry | Infertility | Anorexia | Abdominal pain |
| Barrett’s                     | Asymptomatic or incidental | Nausea and/or vomiting | Mucus | Abdominal mass |
| Respiratory symptoms          | Hyponatraemia | Asymptomatic or incidental | Collapse | Asymptomatic or incidental |
| Bloating                      | Respiratory infection | Ascites | Respiratory symptoms | Anorexia |
| Belching                      | Exacerbation of chronic obstructive pulmonary disease | Anorexia | Haemorrhoids | Dysphagia |
| Throat symptoms               | Abdominal pain | Other/missing/not stated/not known | Urinary symptoms | Change in bowel habit |
| Hiatus hernia                 | Back pain  | Liver | Dyspepsia |
| Odynophagia                   | Liver symptoms/signs | Upper gastrointestinal symptoms |
| Other/missing/not stated/not known | Confusion | Disordered sensation lower limbs | Liver |
| Malaise                       | Ascites | Pancreatitis/chronic |
| Collapse                      | Colitis/inflammatory bowel disease | Steatorrhoea |
| Change in bowel habit         | Other/missing/not stated/not known | Lymphadenopathy |
| Pain (other)                  | Urinary symptoms |
| Headache                      | Other/missing/not stated/not known |
| Lower limb oedema             |
| Mandated referral under NICE guidelines (or good clinical practice) | Clear evidence for mandated urgent referral as per NICE CG27 |
|---------------------------------------------------------------|-------------------------------------------------------------|
| Possible referral under NICE guidelines                       | Good clinical medicine would mandate urgent referral       |
|                                                               | Possible mandated urgent referral as per NICE CG27—but duration dependent |
|                                                               | Possible mandated urgent referral as per NICE CG27—but severity dependent |
|                                                               | Possible mandated urgent referral as per NICE CG27—but location dependent |
|                                                               | Possible mandated urgent referral as per NICE CG27—but dependent upon sense of abnormality |
|                                                               | Possible mandated urgent referral as per NICE CG27—other |
| Mandated investigation under NICE guidelines                   | Clear evidence of mandated investigation as per NICE CG27 |
| Possible investigation under NICE guidelines                   | Possible mandated investigation as per NICE CG27—but duration dependent |
|                                                               | Possible mandated investigation as per NICE CG27—but severity dependent |
|                                                               | Possible mandated investigation as per NICE CG27—but location dependent |
|                                                               | Possible mandated investigation as per NICE CG27—but dependent upon sense of abnormality |
|                                                               | Possible mandated investigation as per NICE CG27—other |
| No action under NICE guidelines                                | No mandated action from NICE CG27                            |

**Table A2. NICE guideline referral categories based on clinical presentation**

**Sensitivity analysis**

We performed several sensitivity analyses for key analytical aspects, using alternative parameterisations of the three variables:

- Primary-care interval
- Investigation use in primary care
- Clinical presentation

Primary-care interval is positively skewed, with a large number of zero values. The analysis (presented in the main text) examines 'mean differences' in primary-care interval associated with investigation use. Although the use of bootstrap estimation means that inference is appropriate, we also performed a sensitivity analysis based on a binary categorisation of primary-care interval into 0–14 and 15+ days. Results are presented in Appendix Table A3.

Investigation use can be parameterised as a binary yes/no variable (as in the main text)—or as an ordered categorical variable based on the number of investigations (used in sensitivity analysis). Specifically, the number of investigations was parameterised as an ordered categorical variable (0, 1, 2 or more investigations) based on counts of the five individual investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy). Results are presented in Appendix Table A4.

In the main analysis presented, we adjust for clinical presentation using five groups based on NICE guideline referral categories (Appendix Table A2). In sensitivity analysis adjustment for clinical presentation was made on the basis of presenting symptom(s) (Appendix Table A1) and based on this classification, but allowing the effect of symptom to vary by age. We also explored adjusting for the more detailed 14-group classification based on NICE guidelines (Appendix Table A2). Results are presented in Appendix Table A6.

**Supplementary analysis**

We performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the number of days between referral from primary care and the first patient contact in secondary care). If this hypothesis were true, it might offset the differences in primary-care interval. We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use. Results are presented in Appendix Table A6.

For ovarian and oesophageal cancers 'possible referrals' were grouped with ‘no action’ in multivariable analysis because of small numbers, similarly age 15–44 years is grouped with age 55–64 years for pancreatic cancer because of small numbers.
### Table A3. Sensitivity analysis using alternative parameterisation of primary-care interval

| Cancer      | Number of cases | Adjusted for age, sex, and the NICE referral category based on presenting symptoms | OR (95% CI) for 15+ days primary-care interval (compared with 0–14 days) adjusted for age, sex, and clinical presentation | P-value |
|-------------|-----------------|---------------------------------------------------------------------------------|------------------------------------------------------------------|---------|
| Colorectal  | Not investigated Investigated | Reference 25.7 (19.5–31.7)                                              | Reference 4.6 (3.7–5.6)                                              | <0.001  |
| Ovarian     | Not investigated Investigated | Reference 18.4 (12.2–25.5)                                              | Reference 4.2 (2.3–7.9)                                              | <0.001  |
| Lung        | Not investigated Investigated | Reference 23.6 (16.8–30.0)                                              | Reference 3.8 (2.8–5.2)                                              | <0.001  |
| Oesophageal | Not investigated Investigated | Reference 22.3 (13.2–32.4)                                              | Reference 4.1 (2.8–6.1)                                              | <0.001  |
| Pancreatic  | Not investigated Investigated | Reference 17.1 (–1.9–30.6)                                              | Reference 4.4 (2.1–9.2)                                              | <0.001  |
| Stomach     | Not investigated Investigated | Reference 29.3 (14.0–45.8)                                              | Reference 5.7 (3.1–10.6)                                              | <0.001  |

Abbreviations: CI = confidence interval; NICE = National Institute for Health and Care Excellence; OR = odds ratio. Results presented in bold italics are those from Table 4. This sensitivity analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.

### Table A4. Sensitivity analysis using alternative parameterisation of investigation use in primary care

| Cancer      | Number of cases | Adjusted for age, sex, and the NICE referral category based on presenting symptoms | Number of cases | Adjusted for age, sex, and the NICE referral category based on presenting symptoms |
|-------------|-----------------|---------------------------------------------------------------------------------|-----------------|---------------------------------------------------------------------------------|
| Colorectal  | Not investigated Investigated | Reference 25.7 (19.5–31.7)                                              | 1031             | Reference 21.3 (15.1–30.0)                                              |
|             |                 | One 923                                                                      | 17.0 (6.9–24.7)  | 16.2 (6.6–24.8)                                                              |
|             |                 | Two  157                                                                     | 332             | Reference 17.1 (7.7–28.8)                                              |
|             |                 | No investigations                                                            | 82              | Reference 4.8 (–14.4–16.7)                                              |
|             |                 | One  148                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two  36                                                                     | 315             | 41.3 (20.2–62.5)                                                             |
| Ovarian     | Not investigated Investigated | Reference 18.4 (12.2–25.5)                                              | 92              | Reference 20.1 (11.0–30.6)                                              |
|             |                 | One  147                                                                     | 809             | 13.6 (6.0–21.2)                                                              |
|             |                 | Two  90                                                                     | 312             | 17.0 (6.9–24.7)                                                             |
|             |                 | No investigations                                                            | 82              | 16.2 (6.6–24.8)                                                             |
|             |                 | One  162                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two  36                                                                     | 315             | 41.3 (20.2–62.5)                                                             |
| Lung        | Not investigated Investigated | Reference 23.6 (16.8–30.0)                                              | 1031             | Reference 21.3 (15.1–30.0)                                              |
|             |                 | One 923                                                                      | 17.0 (6.9–24.7)  | 16.2 (6.6–24.8)                                                              |
|             |                 | Two 157                                                                     | 332             | Reference 17.1 (7.7–28.8)                                              |
|             |                 | No investigations                                                            | 82              | Reference 4.8 (–14.4–16.7)                                              |
|             |                 | One 148                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two 36                                                                      | 315             | 41.3 (20.2–62.5)                                                             |
| Oesophageal | Not investigated Investigated | Reference 22.3 (13.2–32.4)                                              | 1031             | Reference 21.3 (15.1–30.0)                                              |
|             |                 | One 923                                                                      | 17.0 (6.9–24.7)  | 16.2 (6.6–24.8)                                                              |
|             |                 | Two 157                                                                     | 332             | Reference 17.1 (7.7–28.8)                                              |
|             |                 | No investigations                                                            | 82              | Reference 4.8 (–14.4–16.7)                                              |
|             |                 | One 148                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two 36                                                                      | 315             | 41.3 (20.2–62.5)                                                             |
| Pancreatic  | Not investigated Investigated | Reference 17.1 (–1.9–30.6)                                              | 1031             | Reference 21.3 (15.1–30.0)                                              |
|             |                 | One 923                                                                      | 17.0 (6.9–24.7)  | 16.2 (6.6–24.8)                                                              |
|             |                 | Two 157                                                                     | 332             | Reference 17.1 (7.7–28.8)                                              |
|             |                 | No investigations                                                            | 82              | Reference 4.8 (–14.4–16.7)                                              |
|             |                 | One 148                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two 36                                                                      | 315             | 41.3 (20.2–62.5)                                                             |
| Stomach     | Not investigated Investigated | Reference 29.3 (14.0–45.8)                                              | 1031             | Reference 21.3 (15.1–30.0)                                              |
|             |                 | One 923                                                                      | 17.0 (6.9–24.7)  | 16.2 (6.6–24.8)                                                              |
|             |                 | Two 157                                                                     | 332             | Reference 17.1 (7.7–28.8)                                              |
|             |                 | No investigations                                                            | 82              | Reference 4.8 (–14.4–16.7)                                              |
|             |                 | One 148                                                                     | 162             | 29.9 (10.3–58.1)                                                             |
|             |                 | Two 36                                                                      | 315             | 41.3 (20.2–62.5)                                                             |

Abbreviations: CT = computed tomography; MRI = magnetic resonance tomography; NICE = National Institute for Health and Care Excellence. The numbers in these two groups (for all cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy). Results presented in bold italics are those from Table 4. With a single exception (pancreatic cancer) primary-care investigations were associated with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care investigations, compared with those who had one. For lung and ovarian cancer, investigation use was associated with longer primary-care interval, but delay was not additionally longer among people with two or more primary-care investigations, compared with only one.
In order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals among investigated patients, we examined the association between investigations in primary care and the referral interval, and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic). Although the differences in referral interval among investigated and non-investigated patients are small they are positive for all cancers except for pancreatic (i.e., referral intervals are not shorter among investigated patients). Consequently, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated for all cancers except pancreatic cancer. Therefore, overall there is no evidence that longer primary-care intervals are offset by shorter referral intervals among patients who were investigated in primary care.

Table A5. Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category

| NICE referral category | Number of cases | Adjusted for age, sex, and main (5) NICE referral categories based on presenting symptoms | Adjusting for age and sex and detailed (14) NICE referral categories | Adjusting age and sex and for clinical presentation using main presenting symptom | Adjusting for age and sex and for clinical presentation using main presenting symptom (allowing the effect of symptom to vary by age) |
|-----------------------|----------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Colorectal            | Not investigated | 967/1144 | Reference 25.7 (19.5–31.7) | Reference 24.6 | Reference 26.5 | Reference 26.2 |
| Ovarian               | Not investigated | 105/240 | Reference 18.4 (12.2–25.5) | Reference 18.5 | Reference 17.8 | Reference 18.1 |
| Lung                  | Not investigated | 294/1200 | Reference 23.6 (16.8–30.0) | Reference 23.9 | Reference 20.1 | Reference 20.8 |
| Oesophageal           | Not investigated | 293/220 | Reference 22.3 (13.2–32.4) | Reference 22.7 | Reference 23.4 | Reference 23.0 |
| Pancreatic            | Not investigated | 81/246 | Reference 17.1 (–19.3–30.6) | Reference 14.9 | Reference 13.9 | Reference 16.0 |
| Stomach               | Not investigated | 98/148 | Reference 29.3 (14.0–45.8) | Reference 28.4 | Reference 27.7 | Reference 28.0 |

Abbreviation: NICE = National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4.

Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category.

Table A6. Supplementary analysis. The association between investigation use and referral interval (defined as period from day of referral to day when patient was first seen at hospital)

| Primary-care interval | Number of cases | Adjusted for age, sex, and the NICE referral category of presenting symptoms | Referral interval | Number of cases | Adjusted for age, sex, and the NICE referral category of presenting symptoms | Pre-hospital interval | Number of cases | Adjusted for age, sex, and the NICE referral category of presenting symptoms |
|-----------------------|----------------|---------------------------------------------------------------------------------|-----------------|----------------|---------------------------------------------------------------------------------|-----------------------|----------------|--------------------------------------------------------------------------------|
| Colorectal            | Not investigated | 967/1144 | Reference 25.7 (19.5–31.7) | 946/1120 | Reference 5.1 (2.1–8.7) | 946/1120 | Reference 28.4 (21.9–34.9) |
| Ovarian               | Not investigated | 105/240 | Reference 18.4 (12.2–25.5) | 101/236 | Reference 1.6 (–5.0–4.6) | 101/238 | Reference 18.7 (10.9–27.4) |
| Lung                  | Not investigated | 294/1200 | Reference 23.6 (16.8–30.0) | 290/1165 | Reference 4.5 (–1.6–10.1) | 290/1165 | Reference 28.6 (19.4–36.8) |
| Oesophageal           | Not investigated | 293/220 | Reference 22.3 (13.2–32.4) | 283/215 | Reference 4.5 (–2.2–13.3) | 283/215 | Reference 29.1 (18.2–42.5) |
| Pancreatic            | Not investigated | 81/246 | Reference 17.1 (–19.3–30.6) | 78/241 | Reference 9.4 (–33.2–3.1) | 78/241 | Reference 7.4 (–15.6–30.3) |
| Stomach               | Not investigated | 98/148 | Reference 29.3 (14.0–45.8) | 95/141 | Reference 11.9 (5.1–26.7) | 95/141 | Reference 41.8 (21.5–63.4) |

Abbreviation: NICE = National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4.